CompletedPhase 2NCT02595983
The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant
Studying Amyloidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alnylam Pharmaceuticals
- Principal Investigator
- John Vest, MDAlnylam Pharmaceuticals
- Intervention
- Revusiran(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2017
Study locations (6)
- Clinical Trial SIte, Paris, France
- Clinical Trial SIte, Münster, Germany
- Clinical Trial SIte, Porto, Portugal
- Clinical Trial SIte, Majorca, Spain
- Clinical Trial Site, Umeå, Sweden
- Clinical Trial SIte, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02595983 on ClinicalTrials.govOther trials for Amyloidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07560306[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid CardiomyopathyBrigham and Women's Hospital
- RECRUITINGNCT07494656A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in GermanyPfizer
- RECRUITINGPHASE4NCT07298044A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to AcoramidisBayer
- RECRUITINGPHASE2NCT07285044The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasMayo Clinic
- RECRUITINGNCT07218705A Study Of MCG In Cardiac AmyloidosisMayo Clinic
- ENROLLING BY INVITATIONPHASE2NCT06723015Tau PET Outcomes With Anti-amyloid ImmunotherapiesMayo Clinic
- RECRUITINGNCT07213297Comprehensive Program for Hereditary Transthyretin AmyloidosisHospital de Alta Complejidad en Red
- RECRUITINGPHASE1NCT06790394Test-retest Study With [18F]FBB in Cardiac AmyloidosisLife Molecular Imaging GmbH